vs
Side-by-side financial comparison of Hologic (HOLX) and Liberty Energy Inc. (LBRT). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $1.0B, roughly 1.0× Liberty Energy Inc.). Hologic runs the higher net margin — 17.1% vs 2.2%, a 14.9% gap on every dollar of revenue. On growth, Liberty Energy Inc. posted the faster year-over-year revenue change (4.5% vs 2.5%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -6.2%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Liberty Energy Inc. is a North American energy services provider specializing in hydraulic fracturing and well completion solutions for oil and gas operators. It serves clients across major U.S. shale basins, offering low-emission equipment and tailored support to optimize well productivity.
HOLX vs LBRT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.0B |
| Net Profit | $179.1M | $22.6M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 2.2% |
| Net Margin | 17.1% | 2.2% |
| Revenue YoY | 2.5% | 4.5% |
| Net Profit YoY | -10.9% | 64.8% |
| EPS (diluted) | $0.79 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $1.0B | $947.4M | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $1.0B | $977.5M | ||
| Q4 24 | $1.0B | $943.6M | ||
| Q3 24 | $988.0M | $1.1B | ||
| Q2 24 | $1.0B | $1.2B |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $179.1M | $13.7M | ||
| Q3 25 | $187.2M | $43.1M | ||
| Q2 25 | $194.9M | $71.0M | ||
| Q1 25 | $-17.4M | $20.1M | ||
| Q4 24 | $201.0M | $51.9M | ||
| Q3 24 | $178.6M | $73.8M | ||
| Q2 24 | $194.5M | $108.4M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | 20.6% | ||
| Q3 25 | 55.6% | 18.7% | ||
| Q2 25 | 56.3% | 22.1% | ||
| Q1 25 | 37.5% | 22.1% | ||
| Q4 24 | 56.8% | 21.4% | ||
| Q3 24 | 56.4% | 26.2% | ||
| Q2 24 | 55.4% | 27.9% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 22.6% | 1.9% | ||
| Q3 25 | 22.6% | -0.3% | ||
| Q2 25 | 24.9% | 3.6% | ||
| Q1 25 | -0.7% | 1.9% | ||
| Q4 24 | 22.5% | 2.6% | ||
| Q3 24 | 23.3% | 9.4% | ||
| Q2 24 | 24.1% | 12.2% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 17.1% | 1.3% | ||
| Q3 25 | 17.8% | 4.5% | ||
| Q2 25 | 19.0% | 6.8% | ||
| Q1 25 | -1.7% | 2.1% | ||
| Q4 24 | 19.7% | 5.5% | ||
| Q3 24 | 18.1% | 6.5% | ||
| Q2 24 | 19.2% | 9.3% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.79 | $0.08 | ||
| Q3 25 | $0.84 | $0.26 | ||
| Q2 25 | $0.86 | $0.43 | ||
| Q1 25 | $-0.08 | $0.12 | ||
| Q4 24 | $0.87 | $0.31 | ||
| Q3 24 | $0.75 | $0.44 | ||
| Q2 24 | $0.82 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $699.1M |
| Total DebtLower is stronger | $2.5B | $7.1M |
| Stockholders' EquityBook value | $5.2B | $1.9B |
| Total Assets | $9.2B | $4.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $699.1M | ||
| Q4 25 | $2.4B | $27.6M | ||
| Q3 25 | $2.2B | $13.5M | ||
| Q2 25 | $1.9B | $19.6M | ||
| Q1 25 | $1.6B | $24.1M | ||
| Q4 24 | $2.0B | $20.0M | ||
| Q3 24 | $2.3B | $23.0M | ||
| Q2 24 | $2.4B | $30.0M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $2.5B | $246.6M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $190.5M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $5.2B | $2.1B | ||
| Q3 25 | $5.0B | $2.1B | ||
| Q2 25 | $4.8B | $2.0B | ||
| Q1 25 | $4.6B | $2.0B | ||
| Q4 24 | $4.8B | $2.0B | ||
| Q3 24 | $5.1B | $2.0B | ||
| Q2 24 | $5.0B | $1.9B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $9.2B | $3.6B | ||
| Q3 25 | $9.0B | $3.5B | ||
| Q2 25 | $8.8B | $3.4B | ||
| Q1 25 | $8.5B | $3.4B | ||
| Q4 24 | $8.7B | $3.3B | ||
| Q3 24 | $9.2B | $3.3B | ||
| Q2 24 | $8.9B | $3.2B |
| Q1 26 | — | 0.00× | ||
| Q4 25 | 0.48× | 0.12× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.10× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | 13.1% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $195.4M | ||
| Q3 25 | $355.1M | $51.5M | ||
| Q2 25 | $343.3M | $170.6M | ||
| Q1 25 | $169.4M | $192.1M | ||
| Q4 24 | $189.3M | $177.3M | ||
| Q3 24 | $367.0M | $244.5M | ||
| Q2 24 | $405.8M | $248.2M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $-10.0M | ||
| Q3 25 | $341.4M | $-67.2M | ||
| Q2 25 | $330.5M | $33.1M | ||
| Q1 25 | $153.9M | $58.2M | ||
| Q4 24 | $172.5M | $-26.2M | ||
| Q3 24 | $350.6M | $77.9M | ||
| Q2 24 | $385.3M | $112.2M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | -1.0% | ||
| Q3 25 | 32.5% | -7.1% | ||
| Q2 25 | 32.3% | 3.2% | ||
| Q1 25 | 15.3% | 6.0% | ||
| Q4 24 | 16.9% | -2.8% | ||
| Q3 24 | 35.5% | 6.8% | ||
| Q2 24 | 38.1% | 9.7% |
| Q1 26 | — | 13.1% | ||
| Q4 25 | 1.4% | 19.8% | ||
| Q3 25 | 1.3% | 12.5% | ||
| Q2 25 | 1.3% | 13.2% | ||
| Q1 25 | 1.5% | 13.7% | ||
| Q4 24 | 1.6% | 21.6% | ||
| Q3 24 | 1.7% | 14.6% | ||
| Q2 24 | 2.0% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 14.28× | ||
| Q3 25 | 1.90× | 1.20× | ||
| Q2 25 | 1.76× | 2.40× | ||
| Q1 25 | — | 9.55× | ||
| Q4 24 | 0.94× | 3.42× | ||
| Q3 24 | 2.05× | 3.31× | ||
| Q2 24 | 2.09× | 2.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LBRT
Segment breakdown not available.
